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Solid organ transplant patients are susceptible to
rare and unusual dermatoses as a result of their
chronic immunosuppression. Trichodysplasia spinu-
losa (TS) is one such rare clinical entity observed
predominantly in immunosuppressed patients with a
history of either solid organ transplantation on
immunosuppressive therapy or hematologic malig-
nancies treated with chemotherapy. Herein we
present 2 cases of TS that were successfully treated
with compounded topical cidofovir.CASE 1
A 36-year-old African-American man with a
kidney transplant related to end-stage renal disease
from uncontrolled hypertension presented with a
6-month history of a skin-colored follicular eruption
beginning on the central part of the face and
progressing to involve his entire body. The eruption
occurred 8 months after transplantation, and his
immunosuppressant regimen included myco-
phenolate mofetil, tacrolimus, and prednisone.
Prior treatments included topical antifungals, metro-
nidazole cream, imiquimod 5% cream, and cidofovir
1% cream as well as oral valganciclovir for 1 month,
all of which were ineffective.
Physical examination found skin-colored to
lightly erythematous follicular papules and follicular
spinelike projections (Fig 1, A). These spines were
distributed densely in hair-bearing skin on the head
and neck andmore sparsely throughout the trunk and
extremities. His nose was disfigured with markedly
thickened and pebbled skin. There was madarosis of
the eyebrows and a leonine facies appearance.the Departments of Dermatologya and Internal Medicine,d
egon Health and Science University; Department of Derma-
logy, Drexel Universityb; and Department of Dermatology,
iversity of Texas Southwestern Medical Center.c
ing sources: None.
icts of interest: None declared.
spondence to: Justin J. Leitenberger, MD, 3303 SW Bond Ave
5D, Portland, OR 97239. E-mail: leitenbe@ohsu.edu.Histopathology found increased cellularity of the
nucleated eosinophilic inner root sheath cells
with trichohyalin granules. There were also perinu-
clear eosinophilic globules consistent with TS.
Polymerase chain reaction for the NCCR, LT1, and
VP1 regions of the TS polyomavirus (TSPyV)
confirmed the presence of the virus in a biopsy
specimen. Complete sequencing of this isolate found
that the strain was 99.98% identical to the WK164
strain.1
We began treatment with compounded topical
cidofovir 3% cream and weekly monitoring of renal
function and blood counts. He tolerated using the
medicine once daily to his head and neck and then
subsequent use to his extremities. He began showing
improvement at 1 month, and within 3 months his
skin was much smoother with resolution of the
follicular spines and regrowth of his eyebrows
(Fig 1, B).CASE 2
A 62-year-old Haitian man with a kidney
transplant secondary to end-stage renal disease
for hypertension and type II diabetes had a
quickly evolving pruritic facial eruption, which
began 6 months after transplantation. His immu-
nosuppressant regimen included mycophenolateJAAD Case Reports 2015;1:S33-5.
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Fig 1. A, Presentation of multiple follicular spines, madarosis, and leonine facies. B, Smoother
skin in affected areas after topical cidofovir 3% cream twice daily for 3 months.
Fig 2. A, Diffuse small hyperpigmented papules with spiny projections. B, Resolution of
lesions with smoother skin after 2 months of twice-daily topical cidofovir 3% cream.
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treatments included topical cidofovir 1% cream.
On physical examination, there were diffuse small
flesh-colored and hyperpigmented papules with
central spiny projections on bilateral external ears
and frontal/crown of scalp and face, with fewer such
lesions on the neck; there was madarosis and
thickened skin of the medial bilateral cheeks and
nose (Fig 2, A).
Histopathology found mild follicular dilatation
and keratotic plugging within the infundibulum.
There was dystrophy of the inner root sheath along
with pink irregular trichohyalin granules and
apoptotic cells (Fig 3).
Treatment with topical cidofovir 3% cream
applied twice daily to the affected areas resulted in
improvement of his eruption within 2 months (Fig 2,
B).
DISCUSSION
TS is a rare clinical entity observed predominantly
in immunosuppressed patients with a history of
either solid organ transplantation on immuno-
suppressive therapy or hematologic malignanciestreated with chemotherapy. TS often presents with
numerous flesh-colored to erythematous papules
featuring a central keratotic follicular spine. The
distribution favors the glabella, mid-face, chin, and
ears and less so the trunk and extremities. There are
varying degrees of alopecia in areas of high follicular
density, such as on the face, although the scalp is less
affected.2 Lesions in TS are frequently asymptomatic
but may be associated with mild pruritus. Nasal
disfigurement akin to that seen in sarcoidosis and
rosacea may develop from thickening of the skin
resulting in leonine facies.3
TS was previously identified under various
monikers including viral-associated trichodysplasia,
cyclosporine-induced folliculodystrophy, pilomatrix
dysplasia, and trichodysplasia of immunosuppres-
sion.4 Since the original description by Izakovic
et al,5 the histologic findings of TS are highly
distinctive and unique. Light microscopy shows
pronounced distention of anagen follicles with
abnormal maturation, and inner root sheath cells
contain abundant trichohyalin granules. In 1999,
Haycox et al,6 used electron microscopy to show
the presence of intranuclear viral particles of the
Fig 3. Histopathology of TS with increased cellularity of
nucleated eosinophilic inner root sheath cells with tricho-
hyalin granules.
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genome, Van der Meijden et al,7 recently determined
TS to be caused by a new human polyomavirus
and named it trichodysplasia spinulosa-associated
polyomavirus (TSPyV).
The seroprevalence of TSPyV appears to be high
in the healthy population; however, clinical
manifestations have thus far only been observed
in immunosuppressed individuals, among whom
viral seroprevalence approaches 90%.8 Renal and
renal-pancreas transplant patients account for
40% of cases of TS; cardiac transplant patients
comprise another 20%. Other affected patients have
medical histories significant for preeB-cell or T-cell
acute lymphoblastic leukemia, chronic lymphocytic
leukemia, lung transplantation, or lupus erythe-
matosus.9
It has been hypothesized that the patho-
physiology of TS lesions may involve unabated
proliferation of inner root sheath cells infected by
TSPyV. Ki-67 staining of lesional cells is found to be
strongly positive, indicating rapid proliferation of the
inner root sheath cells.10
Clinical improvement of lesions may be noted
with either decreasing or discontinuing immuno-
suppressive therapy, although the latter is not
always a viable option for solid organ transplant
recipients. Resolution has also been reported
after treatment of the underlying hematologic
disease. Treatment with either oral valganciclovir or
topical cidofovir of 1% to 3% is found to be successful
in case reports.11,12 Additionally, improvement of
lesions has been described in isolated cases
with use of oral or topical retinoids (eg, tazarotene
0.5% gel).13These 2 cases uniquely highlight the efficacy of
topical cidofovir 3% cream as a potent therapy for
treatment-refractory TS. Both patients did not
respond to cidofovir 1% cream with several months
of application, and the higher concentration was
found to be efficacious. Because of its toxicity,
cidofovir requires specialty pharmacy compounding
in a class II laminar flow hood. Monitoring of serum
blood urea nitrogen and creatinine is recommended
weekly for the first month, then biweekly thereafter,
particularly in kidney transplant recipients. A
complete blood count should be monitored monthly
while on therapy.
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